PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist originally developed from Melanotan II. It is FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women and is studied for male sexual dysfunction.
Quick facts
- Half-life
- ~2.7 hours
- Administration
- Subcutaneous injection / Nasal spray
- Primary use
- Sexual health, libido
How it works
PT-141 activates melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system, directly influencing sexual arousal pathways in the brain — unlike PDE5 inhibitors which work peripherally on blood flow.
Reported benefits
- Increased sexual desire and arousal
- Effective for both male and female sexual dysfunction
- Central mechanism independent of cardiovascular effects
- FDA-approved for HSDD in women
Typical dosing protocol
Dosing
1–2 mg subcutaneously, 45 minutes before activity. Start low to assess tolerance.
Cycle length
As needed — not for daily use
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Common side effects include nausea, flushing, and transient blood pressure changes. Not for use with cardiovascular conditions. Consult a healthcare professional before use.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.